Canine Mast Cell Tumors and Soft Tissue Sarcomas - Comprehensive Study Notes
Mast Cell Tumors (MCT)
General approach
Most canine mast cell tumor (MCT) patients present with a mass and otherwise feel well; the mass is the primary issue.
Treatment is most commonly surgical excision with margins; goal is complete excision with normal tissue margins.
If cells spill out of the tumor or margins are not clean, a larger surgical margin is often required to reduce residual disease.
Tumor grade matters: low-grade variants have a high likelihood of cure after complete excision; high-grade variants may require adjunctive chemotherapy due to risk of residual microscopic disease in the microcirculation.
If completely excised but high-grade, adjunctive chemotherapy is usually recommended because microscopic cells may have already disseminated.
In general, MCTs are highly treatment-responsive, but durable control is the key goal.
Surgical margins and residual disease
Carve-out of the tumor without a margin of normal tissue risks leaving behind residual cells (as per pathologist).
When margins are inadequate, adjuvant therapy is often necessary to mop up residual microscopic disease.
When the tumor is too large for complete excision
Local control options include either surgery or radiation therapy (RT).
If surgery cannot achieve complete local control, radiation is used; however, RT alone is not ideal due to tumor heterogeneity and radioresistant clones.
Literature suggests that RT alone yields limited durable control, with 1-year local control around
approximately 50%
(about 50%).
Neoadjuvant strategies can be used: neoadjuvant radiation therapy or neoadjuvant chemotherapy to shrink the tumor before surgical excision.
Neoadjuvant therapy and overall strategy
MCTs are often quite responsive; neoadjuvant chemotherapy is commonly used because it is less expensive and more readily available than neoadjuvant radiotherapy.
Goal of neoadjuvant therapy: shrink tumor to facilitate local control with surgery.
Incomplete excision and scar revision (scary vision)
If pathology confirms incomplete excision, the best option is usually a second, more extensive surgery called scar revision, resecting the scar with margins similar to the native tumor.
Scar revision is a hefty, typically costlier, yet effective approach to eradicate residual microscopic disease in the wound bed.
Historically, there was a belief that completely excised tumors would never recur; data show recurrences can still happen, though not uniformly.
If surgery is not feasible or owners decline surgery, radiation of the scar is an acceptable alternative.
Radiation control is better when residual disease is minimal compared to treating the primary bulky tumor.
Local control data: one year control is better when residual disease is microscopic than when bulky disease persists after primary excision.
Other local approaches for incomplete excision include adjuvant radiotherapy or chemotherapy, depending on owner resources and tumor behavior.
Surveillance, prognosis, and literature data
Surveillance can be considered with the understanding that recurrences occur, but rates vary.
A notable study from Colorado State University (large cohort) found that about 23% of incompletely excised grade II–III MCTs recurred locally, while the majority did not recur after surveillance when owners opted against re-surgery.
This information can help counsel owners about prognosis and likelihood of recurrence, and inform decisions about surveillance versus additional treatment.
Prognostic factors: patient-, tumor-, and therapy-related
Patient-related factors: general health and systemic illness impact prognosis and treatment tolerance.
Tumor-related factors: location, grade, size, growth rate, mitotic index, proliferation markers, and molecular features.
Location-specific prognostic aspects:
Tumors in mucous membranes (mouth, muzzle, genito-urinary regions, conjunctiva) behave more aggressively and often warrant adjuvant therapy even if histology appears low-grade.
Oral and muzzle lesions tend to have worse prognosis than cutaneous lesions.
Stage and TNM considerations:
TNM staging is not consistently prognostic for MCTs; many oncologists focus on tumor grade, location, and margins for prognosis rather than relying solely on stage.
Tumor biology: size, growth rate, and microscopic features influence prognosis.
Molecular and prognostic panel information is increasingly used to refine prognosis and guide therapy.
Prognostic testing and panels
Prognostic panels for mast cell tumors analyze multiple markers to better predict behavior and guide treatment intensity.
The panel includes proliferation markers and other prognostic indicators (e.g., mitotic index, PCNA, Ki-67, microvessel density) to estimate tumor aggressiveness.
Cost and utility:
The panel is typically around $4300; used to help decide whether to pursue aggressive treatment or surveillance.
How panels influence decision-making:
If panel suggests low proliferative activity and low risk of recurrence, surveillance may be reasonable.
If panel shows signs of higher risk, clinicians may push for more aggressive adjuvant therapy.
Proliferation and vascular markers:
Proliferation markers include mitotic index and PCNA; higher values indicate more rapid cell turnover.
Microvessel density (MVD) relates to angiogenesis and tumor aggressiveness.
Therapeutic options and sequencing
Conventional cytotoxic chemotherapy regimens:
Vinca alkaloids (e.g., vincristine, vinblastine) and alkylating agents are commonly studied.
Prednisone often included in regimens due to cytotoxic and anti-inflammatory effects.
Cyclophosphamide is sometimes used in combination protocols.
Prednisone-based neoadjuvant strategies:
Early studies in difficult-to-excise MCTs showed prednisone can induce substantial tumor reduction; one study reported about a 70% response rate with diameter reductions around 50% at maximum tumor diameter before definitive surgery.
Clinically, it’s important to document original tumor size (e.g., circle with Sharpie) before prednisone starts because tumors can appear to disappear and you need to plan margins accordingly.
Potential recurrence after prednisone-only shrinkage necessitates definitive local control with surgery or radiation.
Targeted therapy and immunotherapies (RTK inhibitors and beyond)
Tyrosine kinase receptor inhibitors (RTK inhibitors) such as palladium (toceranib) are used when KIT mutations are present.
KIT mutations occur in roughly 20-40% of MCT cases and predict better response to RTK inhibitors.
If KIT mutation is absent, standard cytotoxic chemotherapy is generally pursued first.
Tumor tissue should be tested to determine mutation status; if mutation is present, prioritize RTK inhibition; otherwise proceed with conventional chemo.
Personalized medicine concept: testing the tumor to tailor therapy improves likelihood of selecting an effective agent.
Immunotherapy (checkpoint inhibitors)
The first monoclonal antibody approved for use in dogs targets immune checkpoints (PD-1/PD-L1 axis).
Mechanism: supports anti-tumor immunity by taking the “brake” off the immune system, countering tumor immune evasion.
The drug discussed in the lecture is referred to as Gilbert Mab in the transcript; PD-1/PD-L1 axis inhibitors are discussed as a targeted immunotherapy option.
Data on efficacy is preliminary; genetic testing to identify PD-L1 overexpression may improve selection of patients who will respond.
Conceptual parallel to human oncology: a minority (roughly 10–20%) of patients respond with meaningful benefit.
Other emerging therapies
Intratumoral strategies including intralesional injections are used in some settings for non-resectable masses (e.g., newer intratumoral agents).
A novel intratumoral agent (often discussed as Stelfonta in canine practice) can be used for non-resectable non-metastatic subcutaneous MCTs located distal to the elbow or hock, or less than 10 cm in diameter for cutaneous masses.- Mechanism involves recruitment of protein kinase C (PKC) signaling to induce tumor necrosis and local destruction, followed by a wound that requires management.
Premedication and anesthesia considerations are important due to potential local inflammatory reactions.
Patients and owners should be counseled about the expected wound and healing process, which typically takes weeks and may create a large wound that requires care.
Practical cautions and owner communication
Always prepare owners for the possibility of incomplete excision and recurrence, and discuss a Plan B (e.g., additional surgery, radiation, or chemotherapy) up front.
When considering aggressive local therapy, especially if surgery is impractical, discuss the balance of cost, morbidity, and likelihood of durable control.
Ethical and practical implications: despite best efforts, cancer may recur or progress; set realistic expectations with owners and provide a clear follow-up plan.
Summary takeaways
Mast cell tumors are generally highly responsive to treatment, but durable control depends on tumor grade, margins, and location.
Complete surgical excision with clean margins remains the gold standard; if margins are uncertain or tumor is high-grade, adjunctive chemo or RT is often warranted.
For non-resectable tumors, RT, neoadjuvant strategies, or novel intratumoral therapies may be appropriate depending on case details.
Prognostic panels and molecular testing are increasingly used to tailor therapy and inform prognosis.
Soft Tissue Sarcomas (STS)
Overview and epidemiology
STS are a diverse group of tumors arising from connective tissues; they account for about
15%
of all skin and subcutaneous tumors in dogs and about half that in cats.
They represent roughly 1% of all malignancies in companion animals.
>20 histologic subtypes exist, but they are treated as a collective group due to similar biologic behavior: locally invasive with a low to moderate risk of metastasis, which is often grade-dependent.
They typically occur in middle-aged to older dogs and cats; no strong breed or sex predilection, though large breed dogs may be overrepresented.
Rhabdomyosarcoma is a notable exception that tends to occur in very young dogs.
General behavior and clinical presentation
Present as slow-growing, non-painful dermal or subcutaneous masses dependently on site.
Symptoms are site-dependent and relate to the structures involved (e.g., fascia, muscle, nerves).
Because they arise from a wide range of connective tissues (fibrous tissue, adipose, vascular, neural, etc.), they can appear nearly anywhere in the body.
Major histologic variants (overview of common topics)
Fibrous tissue origin (fibrosarcoma)
The benign counterpart is fibroma/fibro-osseous variants with potential variants like nodular fasciitis (benign but can be locally aggressive).
Halo variant and other fibrous tissue presentations are noted as part of the fibrous sarcoma spectrum.
Fibrous tumors can be found in skin and subcutis, with predisposition in some breeds.
Nodular fasciitis (humans and animals): rapidly growing benign lesion, often aggressive in growth but not malignant metastasis; requires aggressive management to prevent recurrence.
Fibromitosis (wildlife): benign proliferative fibro-mas in wildlife (deer, rabbits, squirrels) with regional considerations.
Lipomatous tumors (adipose origin) and liposarcoma: a spectrum including lipoma, infiltrating lipoma, and liposarcoma.
Vascular and lymphatic tumors (hemangiomas and hemangiosarcomas): typically malignant with aggressive behavior; hemangiosarcoma has a high metastatic potential.
Nerve sheath tumors (peripheral nerve sheath tumors): can involve large nerves and spinal roots.
Synovial and other mesenchymal tumors: include synovial sarcoma and related entities.
Lipomas and adipose tumors (relevant STS subset)
Lipoma (benign lipomas) are common and usually do not require margins or aggressive surgery; excision is unnecessary unless they cause functional issues.
Intermuscular lipoma: a benign fat tumor that grows between muscles, often in the caudal thigh, presenting as a large, firm mass that can mimic malignancy.
Definitive diagnosis often requires CT imaging and assessment of Hounsfield units to differentiate fat from other tissue components.
CT helps distinguish an intermuscular lipoma from infiltrating lipoma that invades muscle tissue.
Infiltrating lipoma (lipoma with local invasion): although benign and non-metastatic, it can infiltrate into surrounding tissues; may require incisional biopsy to differentiate from liposarcoma and to plan treatment.
Liposarcoma: malignant variant; tends to invade locally and can metastasize; staging and wider margins are important.
Imaging and diagnosis:
CT or MRI can help differentiate lipomas and infiltrating lipomas from liposarcoma by assessing density and invasion into surrounding tissues.
Biopsy (incisional) helps distinguish infiltrating lipoma from liposarcoma when imaging is inconclusive.
Management principles:
Complete excision with clean margins is curative for benign lipomas.
Infiltrating lipomas and liposarcomas require more aggressive management and staging to ensure control.
Vascular and lymphatic tumors
Hemangioma (benign): solar-induced, common in dogs with less dense fur coats; cryotherapy is an effective treatment for cutaneous lesions; surgical excision is sometimes used for larger lesions.
Hemangiosarcoma (malignant): aggressive vascular tumor with a high metastatic rate; difficult to achieve durable local control; typically requires a combination of surgery, radiation, and chemotherapy; systemic disease is common.
Management approach emphasizes aggressive local control when possible, but systemic disease control is crucial; prognosis remains guarded even with multimodal therapy.
Nerve and synovial tumors
Peripheral nerve sheath tumors: arise from nerve sheaths; can involve large portions of nerve trunks; surgical management may require limb amputation or extensive resection to achieve local control in severe cases.
Synovial tumors: include synovial sarcoma and related mesenchymal tumors; a distinct category in the spectrum of STS; management is similar to other STS with surgical excision and adjunctive therapy as indicated.
Osteosarcoma vs synovial tumors: osteosarcoma is a primary bone tumor; synovial-origin tumors may involve joints, whereas true osteosarcoma does not cross joints (cartilage provides some protection); misdiagnosis can occur if the tumor crosses joints; additional imaging (radiographs, CT) and biopsy are necessary for accurate classification.
Diagnostic and treatment implications
Wide surgical excision with clean margins is a cornerstone for many STS, but anatomical location and tissue of origin influence the feasibility of margins and need for adjuvant therapy.
Radiotherapy is a common adjuvant therapy for incompletely excised tumors or where margins are marginal; chemotherapy is used based on tumor type, grade, and metastasis risk.
Staging and prognosis rely on tumor biology (grade), depth, mitotic index, and presence of metastasis rather than solely on size or uncomplicated staging.
Practical takeaways for clinical practice
STS require careful differentiation from benign mimics; imaging (CT/MRI) and biopsy are essential when indicated to plan margins and treatment strategy.
Genetic and immunohistochemical markers can provide prognostic information and guide therapy choices, particularly in challenging cases or when considering targeted therapies.
Multimodal therapy (surgery + radiation + chemotherapy) is common in intermediate- to high-risk STS; the exact combination depends on location, grade, and extent of disease.
Quick reference points
STS incidence: roughly 15% of skin/subcutaneous tumors in dogs; about half that in cats.
Local invasiveness with a relatively low-to-moderate risk of metastasis; metastasis risk increases with higher grade.
Rhabdomyosarcoma is more common in young dogs.
Intermuscular lipoma: CT-diagnostic feature; may appear as a large, firm, non-painful mass in the caudal thigh; CT shows fat density without invasion into adjacent muscles; management may include conservative removal or more extensive excision if needed.
Lipoma vs liposarcoma distinction requires biopsy; infiltrating lipoma behaves aggressively in local tissue but is not metastatic; liposarcoma can metastasize and requires more aggressive staging and treatment.
Closing note on prognosis and practice
Prognosis in STS varies by subtype, grade, location, depth, and completeness of excision; ongoing surveillance and possible adjuvant therapy are often necessary.
In many cases, the goal is to achieve durable local control with acceptable morbidity, while managing the risk of metastasis through tailored therapy.